To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KCA; p110α); mammalian target of rapamycin (mTO


Cancer

INDICATION: Cancer

Patient sample and mouse studies suggest inhibiting the PI3Kα/mTOR pathway could help treat venous malformations. Genetic sequencing identified activating mutations in PI3KCA in venous malformation lesions from

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE